Classical Versus Novel Treatment Regimens
The chapter will define drug insensitivity and drug resistance in the context of Leishmania infections, both cutaneous and visceral, and describe the impact on treatment this may have. The molecular mechanisms of drug resistance of antimonials, and of other standard antileishmanial drugs will be reviewed, and the evidence for novel treatment regimens, to compensate for drug resistance, will be explored.
KeywordsVisceral Leishmaniasis Lipid Formulation Leishmania Species Flagellar Pocket Intracellular Thiol
- Allen S, Neal RA (1989) The in vitro susceptibility of macrophages infected with amastigotes of Leishmania spp. to pentavalent antimonial drugs and other compounds with special relevance to cutaneous leishmaniasis. In: Hart DT (ed) Leishmaniasis. Plenum Publishing Corporation, New York, pp 711–720Google Scholar
- Martin D (2010) Identification and development of new chemical entities to treat visceral leishmaniasis: a bump road. ICOPA XII, Melbourne, Australia: 26Google Scholar
- MMV (2009) Tafenoquine phase I. GSK, UK. http://www.mmv.org/research-development/project-portfolio/tafenoquine
- Roychoudhury J, Ali N (2008) Sodium stibogluconate: therapeutic use in the management of leishmaniasis. Indian J Biochem Biophys 45:16–22Google Scholar